-transparent.png){kind=logo}
Certain monoclonal antibodies (mAbs) to human placental alkaline phosphatase (PLAP) block bromelain cleavage of a 2-kDa segment from each of the two polypeptide chains of PLAP. These mAbs also prevent the release of PLAP from cultured cancer cell surfaces by bromelain. Such proteolysis-blocking mAbs serve as tools to specifically modify the molecular topography of cell surfaces by protease treatment.
Related Publications
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
August 1984,
FEBS letters,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
July 1982,
International journal of cancer,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
January 1983,
Clinical chemistry,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
March 1984,
American journal of human genetics,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
January 1983,
American journal of human genetics,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
January 1984,
Progress in clinical and biological research,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
October 1980,
The Journal of biological chemistry,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
June 1980,
Journal of biochemical and biophysical methods,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
January 1984,
Progress in clinical and biological research,
R Jemmerson, and
J L Millan, and
F G Klier, and
W H Fishman
November 1985,
Experientia,
